- Home
- MPB vs VTYX Comparison
MPB vs VTYX Comparison
Compare MPB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | VTYX |
|---|---|---|
| Founded | 1868 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 713.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MPB | VTYX |
|---|---|---|
| Price | $32.93 | $7.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $14.60 |
| AVG Volume (30 Days) | 88.8K | ★ 1.8M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $208,869,000.00 | N/A |
| Revenue This Year | $26.19 | N/A |
| Revenue Next Year | $28.25 | N/A |
| P/E Ratio | $13.52 | ★ N/A |
| Revenue Growth | ★ 20.73 | N/A |
| 52 Week Low | $22.50 | $0.78 |
| 52 Week High | $33.14 | $10.55 |
Technical Indicators
Market Signals| Indicator | MPB | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 76.85 | 42.39 |
| Support Level | $31.76 | $7.94 |
| Resistance Level | $32.62 | $8.52 |
| Average True Range (ATR) | 0.61 | 0.58 |
| MACD | 0.27 | -0.23 |
| Stochastic Oscillator | 92.40 | 5.44 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.